Impact of Ocrelizumab Vs. Interferon Beta-1a In Delaying The Deterioration Of Patients' Daily Functions and Associated Costs In Relapsing-Remitting Multiple Sclerosis
Abstract
Authors
H Yang ED Duchesneau A Guerin E Ma NP Thomas